A Mint investigation reports that a Bengaluru event billed as India's first "peptide party" was called off after Karnataka's food and drug regulator sought details from the organizers. Around 50 people were expected in Koramangala for music, food and a five-item tasting menu of oral peptides that the organizers say were already commercially available and not prescription-grade.

Peptides are short chains of amino acids, some of which occur naturally in the body and act as messengers influencing hormones, metabolism, inflammation, tissue repair and appetite. Others are made in a lab to mimic, enhance or block those signals, which is how a single word ends up covering both approved diabetes drugs and vials sold on Telegram.

What the party was for

Upsurge Labs, which organized the event, told Mint the plan was a conversation rather than a product launch, with doctors lined up to speak on the clinical side. "India in general has been a little behind when it comes to biotech and biological science conversations that are already mainstream in the West," said brand strategist Aisurya Mishra. The idea followed peptide clubs and workshops in San Francisco longevity circles. Doctors on X were unimpressed, and the regulator followed.

The market the cancellation did not touch

A June report from blockchain analysis firm Chainalysis found grey market peptide transactions exceeding a $100 million run rate in 2026, against roughly $1 million per quarter in 2024. No India-specific figure exists. Mint found platforms selling injectable peptides carrying "research use only" labels, and users who buy from suppliers they consider trustworthy: BPC-157, GHK-Cu, TB-500, semax, selank and retatrutide are the names that recur.

Where the oversight isn't

Injectables sit outside FSSAI's supplement and nutraceutical framework, which covers oral products. India's CDSCO has not approved these peptides for therapeutic use, though it granted Eli Lilly permission to run retatrutide trials. One Bengaluru clinic operator told Mint he has fired five dealers after finding contamination, and that independent testing adds about 20% to cost.

Bottom line

The interesting structural point in the reporting is Dr. Swapneil Parikh's: BPC-157's original patent lapsed, so nobody can profit from trialing it, leaving compounds in limbo without structured clinical data. Canceling one party in Koramangala does nothing about that.